Introduction
============

Intrahepatic cholangiocarcinoma (ICC), a rare malignant tumor derived from the intrahepatic and extrahepatic biliary tract, has a poor prognosis and a high incidence.[@b1-ott-10-5863] Despite the development of novel diagnostic tools and clinical screenings in recent years, the resection rate of ICC is still low and variable (18%--70%) due to a majority of patients being diagnosed at an advanced stage.[@b2-ott-10-5863] Moreover, most of the post-resection patients show recurrence (up to 75%) in the remnant liver after the curative treatment.[@b3-ott-10-5863] Thus, it is important to reveal the underlying mechanism for ICC development.

Ubiquitin-like with PHD and ring finger domains 2 (UHRF2) is a member of the UHRF family proteins, which includes an ubiquitin-like domain, a plant homeodomain, a RING finger domain, and a SET and RING finger-associated (SRA) domain. As a ubiquitin E3 Ligase, UHRF2 was initially identified as a cell cycle regulator by its interaction with the inactive CDK2--cyclin E complex.[@b4-ott-10-5863] Then, UHRF2 was demonstrated to bind to H3K9me2/me3-containing peptides, and interact chromatin-mediated genes with SRA.[@b5-ott-10-5863]--[@b7-ott-10-5863] Recently, it has been further found to function as a key epigenetic regulator by interacting with DNA and histone methyltransferases.[@b8-ott-10-5863],[@b9-ott-10-5863] Recently, the roles of UHRF2 in cancer have emerged; for example, UHRF2 was found to induce the apoptosis of tumor cells by regulating E2F1[@b10-ott-10-5863],[@b11-ott-10-5863] and to reduce the expression of cell cycle-related proteins in lung cancer and malignant glioma, which indicated that UHRF2 functioned as a tumor suppressor.[@b12-ott-10-5863],[@b13-ott-10-5863] More recently, UHRF2 was uncovered to be a promoter of tumor development by inhibiting the expression of tumor suppressor genes, such as p16, p21, and p27, through its action on DNA methylation and histone modification in breast cancer.[@b14-ott-10-5863] Furthermore, high level of UHRF2 was revealed to induce ERK1/2 activity via transcriptional deregulation, and to be negatively associated with the patients' overall survival (OS) in colon cancer, which indicated that UHRF2 might be an oncogene.[@b15-ott-10-5863],[@b16-ott-10-5863] The above results indicate that UHRF2 is a multistructural protein and has a wide range of functions, and its function in tumors depends on the tumor type and cellular context.

Epithelial--mesenchymal transition (EMT) is a multistep biologic process in which the epithelial cells transform to mesenchymal phenotype cells. Now, EMT is deemed as an essential element in tumor metastasis of several epithelial malignancies.[@b17-ott-10-5863] E-cadherin, an important molecule in cell EMT process, localizes at regions of cell-cell contact, which is down-regulation during loss of epithelial cells polarity and gain of mesenchyme cells migratory properties.[@b18-ott-10-5863] So, the expression of E-cadherin is a marker to estimate tumor invasion and metastasis.[@b19-ott-10-5863],[@b20-ott-10-5863] Recently, UHRF2 was demonstrated by proteomics analysis to promote tumor progression by inducing cell EMT.[@b21-ott-10-5863] However, the relationship between UHRF2 and E-cadherin expression in most tumors is still unclear, which needs to be further elaborated.

This study would investigate the expression and functions of UHRF2 in ICC and assess the relationship between UHRF2 and E-cadherin expression in ICC cells and tissues. In addition, the clinical implication of UHRF2 expression in ICC was analyzed.

Patients and methods
====================

Patients and samples
--------------------

Eighteen pairs of frozen tissues from ICC patients were obtained from the tissues center of Zhongshan Hospital, and the ICC tissues were acquired from 139 patients who underwent curative surgical resection at the Department of Liver Surgery of Zhongshan Hospital, Fudan University, between February 2003 and November 2010. Both tumor and peritumor samples were obtained from each patient. Complete removal of tumor nodules including peripheral lymph node, hepatoduodenal ligament, and hepatic bile duct is referred to as curative resection. The histopathologic diagnosis of ICC was according to the World Health Organization standard. The Child Pugh score system was used to assess liver function. The tumor stage of the patients was determined according to the TNM sixth edition of the Union for International Cancer Control. Follow-up data were obtained until February 2015. The median survival time was 18 months (range 4--120 months). This study was approved by the Zhongshan Hospital Research Ethics Committee. All the participants provided an informed consent. All procedures in this study were performed according to the ethical standards of the institutional and/or national research committee and in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Tissue microarrays (TMAs) and immunohistochemistry
--------------------------------------------------

The construction of TMAs and immunohistochemistry were performed as previously described.[@b22-ott-10-5863] Rabbit anti-human UHRF2 monoclonal antibody (1:1,000; Wuhan Boster Biological Technology, Ltd., Wuhan, People's Republic of China) and rabbit anti-human E-cadherin antibody (1:100; Cell Signaling Technology, Danvers, MA, USA) were utilized to detect the levels of UHRF2 and E-cadherin. The density level of strong, moderate, and weak staining was defined as in previous studies.[@b22-ott-10-5863]--[@b24-ott-10-5863] The assessment was performed blindly by two pathologists.

Cell lines and cell culture
---------------------------

Two ICC cell lines, RBE and QBC939, were provided by the Chinese Academy of Sciences Shanghai branch cell bank (Shanghai, People's Republic of China). These two cell lines were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, streptomycin, and penicillin at 37°C in a humidified incubator under 5% CO~2~.

Small interfering RNA
---------------------

Two different siRNA sequences were purchased from Shanghai Genomeditech Company (Shanghai, People's Republic of China). The target sequences are as follows: siRNA1: GTCAGAGTGATACGCAGTT; siRNA2: GGAGATTATGTCTACGTTT. The siRNA and the negative control were transfected using lipofectamine™ 2000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the protocols. The efficiency of silence was determined after 72 hours of transfection.

Cell proliferation, migration, and invasion assays, flow cytometry
------------------------------------------------------------------

Cell proliferation was estimated by cell counting kit-8 assay (Yeason, Shanghai, People's Republic of China). Migration ability was analyzed by wound healing assay. Invasion was evaluated by transwell assay. Cell apoptosis was detected by flow cytometry (Becton Dickinson). Each protocol has been published earlier.[@b23-ott-10-5863]--[@b25-ott-10-5863]

Western blot and quantitative real-time polymerase chain reaction (qRT-PCR)
---------------------------------------------------------------------------

Western blot and immunofluorescence were performed as in our early studies.[@b22-ott-10-5863]--[@b24-ott-10-5863] UHRF2 (1:1,000; Boster) and E-cadherin mABs (1:1,000; Abcam, Cambridge, MA, USA) were used to detect the expression of UHRF2 and E-cadherin (1:1,000) in three ICC cell lines. Tubulin (1:1,000; Cell Signaling Technology) was used as the internal control.

The primers used for PCR are as follows: UHRF2: 5′-GGACCTTCCAATCAGCCATC-3′ (forward), 5′-GACATCTCTGGCATCCACCA-3′ (reverse); E-cadherin: 5′-GAACGCATTGCCACATACAC-3′ (forward), 5′-GAATTCGGGCTTGTTGTCAT-3′ (reverse); tubulin: 5′-CTGCCTGTT GTACCGTGGTG-3′ (forward), 5′-ATGCCAACCTTGAAGCCAGT-3′ (reverse).

Immunofluorescence assays
-------------------------

Cells were treated with 0.1% Triton X-100 for 30 minutes at room temperature. After washing with PBS and blocking with 10% bovine serum albumin for 1 hour, cells were incubated with primary antibody overnight at 4°C. Successively, cells were washed with PBS and treated with secondary antibody for 2 hours, and the cell nuclei were stained by 4′,6-diamidino-2-phenylindole. Finally, the slides were photographed with a fluorescence microscope.

Statistical analysis
--------------------

Quantitative data were analyzed using Student's *t*-test between two groups. Categorical data were analyzed using the *χ*^2^ or Fisher's exact tests. The Kaplan--Meier method was used to determine survival probability, and differences were assessed by the log-rank test. Cox analysis was used to determine independent prognostic factors. A *P*-value of \<;0.05 was considered statistically significant. All analyses were performed using SPSS 21.0 software (IBM Corporation, Armonk, NY, USA).

Results
=======

UHRF2 overexpressed in human cancers
------------------------------------

Firstly, we tried to analyze the expression of UHRF2 in multiple kinds of cancers by referring the Oncomine database. As shown in [Figure 1A](#f1-ott-10-5863){ref-type="fig"}, the mRNA levels of UHRF2 were increased in the tumor tissues compared with normal tissues, including gastric cancer,[@b26-ott-10-5863] colon cancer,[@b27-ott-10-5863] and liver cancer.[@b28-ott-10-5863]

Then four pairs of tissues from ICC patients were randomly chosen to examine UHRF2 protein expression, and we found that UHRF2 expression was much higher in the tumor tissues than that in the corresponding peritumor tissues ([Figure 1B](#f1-ott-10-5863){ref-type="fig"}). Similarly, UHRF2 mRNA was higher in the tumor tissues than in matched adjacent tissues (*P*=0.028; [Figure 1C](#f1-ott-10-5863){ref-type="fig"}). Immunohistochemistry results suggested that the staining intensity of UHRF2 in ICC tissues was characteristically stronger than that in their peritumor tissues (*P*\<;0.001; [Figure 1D and E](#f1-ott-10-5863){ref-type="fig"}). The above results indicated that the UHRF2 level was elevated in ICC tissues.

UHRF2 expression was related to malignant features of ICC
---------------------------------------------------------

UHRF2 expression was knocked down in QBC939 and RBE ICC cell lines by siRNA ([Figure 2A](#f2-ott-10-5863){ref-type="fig"}). Then we chose the most silenced siRNA to investigate whether UHRF2 is related to tumor proliferation, aggressiveness, and apoptosis. The results of cell counting kit-8 assays strongly indicated that the ICC cell proliferation was inhibited after UHRF2 interference on the 4th day ([Figure 2B](#f2-ott-10-5863){ref-type="fig"}). The transwell assay displayed that downregulation of UHRF2 suppressed the invasion of ICC cells ([Figure 2C](#f2-ott-10-5863){ref-type="fig"}), which was in line with the migration assay ([Figure 2D](#f2-ott-10-5863){ref-type="fig"}). Moreover, the assessment of cell apoptosis revealed that UHRF2 interference increased ICC cell apoptosis ([Figure 2E](#f2-ott-10-5863){ref-type="fig"}).

UHRF2 was negatively associated with E-cadherin expression in ICC
-----------------------------------------------------------------

In ICC tissues, UHRF2 and E-cadherin expression exhibited heterogeneity. UHRF2 was restricted to the cytoplasm of ICC cells, while E-cadherin was located at the membranes of the cancer cells. Representative samples are presented in [Figure 3A](#f3-ott-10-5863){ref-type="fig"} (UHRF2^high^/E-cadherin^low^; UHRF2^low^/E-cadherin^high^).

In a previous study, reduction of E-cadherin was reported to correlate with the aggressive feature of tumor.[@b20-ott-10-5863] Here, we found that E-cadherin staining intensity was weak in 63 tissues and UHRF2 staining was negatively related to E-cadherin expression in ICC tissues (*r*[@b2-ott-10-5863]=0.4221, *P*\<;0.001; [Figure 3B](#f3-ott-10-5863){ref-type="fig"}). In RBE and QBC939 cell lines, we also found the expressions of UHRF2 and E-cadherin were opposite ([Figure 3C and D](#f3-ott-10-5863){ref-type="fig"}).

High level of UHRF2 was correlated with the poor prognosis of ICC patients
--------------------------------------------------------------------------

According to the UHRF2 expression, all patients in the TMAs were distributed to two subgroups, including UHRF2^low^ (absence and weak staining) and UHRF2^high^ (moderate and strong staining) groups ([Figure 4A--D](#f4-ott-10-5863){ref-type="fig"}). To determine the clinical significance of UHRF2 expression in ICC patients, survival curves were created, and we found that overexpressed UHRF2 was definitely correlated with the poor prognosis of ICC patients enrolled in this study. The OS rates of ICC patients with UHRF2^low^ were obviously higher than those of patients with UHRF2^high^ (*P*\<;0.001; [Figure 4E](#f4-ott-10-5863){ref-type="fig"}). The 2- and 5-year OS rates in the UHRF2^high^ group were substantially decreased compared with that in the UHRF2^low^ group (22.6% vs 44.2% and 17.7% vs 26.0%, respectively). The cumulative recurrence rates of ICC patients with UHRF2^low^ were much lower than those of patients with UHRF2^high^ (*P*\<;0.001; [Figure 4F](#f4-ott-10-5863){ref-type="fig"}). The 2- and 5-year cumulative recurrence rates in the UHRF2^low^ group were clearly elevated compared with those of the UHRF2^high^ group (80.6% vs 63.6% and 81.0% vs 75.3%, respectively).

The relationship between the clinicopathologic characteristics of ICC and UHRF2 levels was analyzed. Two factors, microvascular invasion (*P*=0.028) and lymph node metastasis (*P*=0.009), were significantly associated with UHRF2 ([Table 1](#t1-ott-10-5863){ref-type="table"}). In univariate analysis, tumor size, multiple tumor, embolus, tumor differentiation, lymphatic metastasis, and UHRF2 expression were predictors for OS and cumulative recurrence of ICC patients ([Table 2](#t2-ott-10-5863){ref-type="table"}). In multivariate Cox proportional hazards model, expression of UHRF2 was an independent prognostic factor for OS (*P*\<;0.001) and cumulative recurrence of ICC patients (*P*=0.034; [Table 2](#t2-ott-10-5863){ref-type="table"}).

Discussion
==========

We found in this study that UHRF2 was overexpressed in ICC tissues, and interference of UHRF2 depressed cancer cell proliferation, invasion, and metastasis and promoted apoptosis. Moreover, we found that the expression of UHRF2 negatively correlated with E-cadherin, loss of which has been linked to poor prognosis of many types of cancer, including ICC. Additionally, high level of UHRF2 was found to be associated with the malignant phenotypes of ICC, including microvascular invasion and lymph nodes metastasis. Finally and importantly, patients with a high level of UHRF2 had poorer OS and high cumulative recurrence rates. These findings indicated that UHRF2 might be a new therapeutic target and a unique prognostic factor.

As an E3 ligase, the understanding of UHRF2 function in cancer experienced a complicated process. Firstly, it was reported to work as a tumor suppressor gene by not only promoting the propagation phase, but also significantly inhibiting the G0/G1 phase.[@b7-ott-10-5863] For example, cancer outlier profile analysis indicated that UHRF2 was down-regulated in several malignant tumors, such as brain and central nervous system cancer.[@b12-ott-10-5863],[@b13-ott-10-5863] Then, it was reported to regulate the post-translational modification of histones, including H3K9ac and H3K14ac, to induce initiation and progression of tumor.[@b9-ott-10-5863],[@b10-ott-10-5863] Meanwhile, UHRF2 was found to interact with hepatitis B core and downregulate acetylation of hepatitis B virus ccc-DNA. A further study has reported its N-domain played an important role in protein degradation or gene transcription.[@b29-ott-10-5863] Recently, overexpression of UHRF2 has been reported in several types of tumors, including breast cancer, lung cancer, brain cancer, and colon cancer. Specially, UHRF2 interacts with EMT-transcription factors, including ZEB1/2 and SNAI1/2, in gastric cancer, which indicates that UHRF2 could silence the expression of E-cadherin through directly binding the promoter region of E-cadherin gene.[@b21-ott-10-5863] All of these suggested UHRF2 overexpression promoted tumor progression and might be a potential hallmark for diagnosis and a therapeutic target. Herein, we have presented the expression and functions of UHRF2 in ICC cells and tissues, particularly the clinical implication of UHRF2 in ICC patients, which indicate that UHRF2 overexpression served as a promoter of ICC.

EMT is a critical mechanism for epithelial tumor development.[@b30-ott-10-5863] EMT is an early factor in metastasis of tumor because mesenchymal phenotype activation and repression of the epithelial phenotype are necessary for the cell to detach from the tumor mass.[@b31-ott-10-5863],[@b32-ott-10-5863] The membrane surface E-cadherin, one of the EMT-related proteins, has a fundamental role in EMT. E-cadherin can be repressed by several EMT-inducing transcription factors, including SNAIL1/2, ZEB1/2 and TWIST. Recently, UHRF2 was demonstrated to regulate the functions of these transcription factors.[@b21-ott-10-5863],[@b31-ott-10-5863] Thus, UHRF2 may indirectly regulate E-cadherin expression. In this study, we showed that the expression of UHRF2 was negatively associated with E-cadherin expression in ICC tissues. Moreover, the interference of UHRF2 in ICC cells upregulated E-cadherin in the ICC cells. The above results lend support to the notion that UHRF2 does make a substantial contribution to ICC progression by regulating E-cadherin.

Although the precise role of interaction of UHRF2 and E-cadherin in tumor development in vitro and in vivo and other EMT markers needs to be further investigated, our results are important, and detection of UHRF2 may be used as a predictor to find the prognosis in noninvasive and nonmetastatic ICC.
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![The expression of UHRF2 in human cancers and ICC patients.\
**Notes:** (**A**) Microarray data analysis of UHRF2 mRNA in gastric cancer, colon cancer, and hepatocellular carcinoma from the publicly available Oncomine database. (**B**) UHRF2 protein expression in randomly selected ICC tissues and their matched peritumor tissues by Western blot. (**C**) Relative expression of UHRF2 among tumor and peritumor tissues using qRT-PCR. (**D**) Positive UHRF2 was observed primarily in the cytoplasm. Representative UHRF2 and H\<E staining are displayed. Scale bar =50 μm, magnification: 200×. (**E**) The density analysis revealed statistical significance of UHRF2 level of 100 cases of patients in TMA samples. \**P*\<;0.05, \*\*\**P*\<;0.001.\
**Abbreviations:** H\<E, hematoxylin and eosin; ICC, intrahepatic cholangiocarcinoma; qRT-PCR, quantitative real-time polymerase chain reaction; TMA, tissue microarray; UHRF2, ubiquitin-like with PHD and ring finger domains 2; IHC, immunohistochemistry.](ott-10-5863Fig1){#f1-ott-10-5863}

###### 

UHRF2 expression resulted in ICC cell proliferation, invasion, migration, and antiapoptosis.

**Notes:** (**A**) UHRF2 expression was interfered by siRNA and confirmed by Western blot and qRT-PCR. GAPDH was used as internal control. (**B**) Cell counting kit-8 assay was used to assess the ability of cell proliferation. (**C**) Transwell assay was used to show the invasion of ICC cells with different UHFR2 expression in 48 hours. Scale bar =100 μm. (**D**) Wound healing assays showed that inhibition of UHRF2 decreased wound healing compared with control cells. Scale bar =100 μm. (**E**) FCM results indicated that anti-UHRF2 caused acceleration of cell apoptosis. The results are mean ± SD of triplicated independent experiments. \**P*\<;0.05, \*\**P*\<;0.01, \*\*\**P*\<;0.001.

**Abbreviations:** FCM, flow cytometry; FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ICC, intrahepatic cholangiocarcinoma; qRT-PCR, quantitative real-time polymerase chain reaction; UHRF2, ubiquitin-like with PHD and ring finger domains 2.
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![UHRF2 was negatively associated with E-cadherin expression in ICC.\
**Notes:** (**A**) High expression of UHRF2 and low expression of E-cadherin, and low expression of UHRF2 and high expression of E-cadherin are shown. Scale bar: 100, 200 μm. (**B**) The relationship between UHRF2 and E-cadherin in ICC patients; the protein expression of UHRF2 was significantly negatively correlated with E-cadherin expression. (**C**) UHRF2 and E-cadherin protein were detected by Western blot analysis. (**D**) Representative immunofluorescent images of UHRF2 and E-cadherin in ICC cell lines are shown. Scale bars =100 μm. \**P*\<;0.05, \*\**P*\<;0.01, \*\*\**P*\<;0.001.\
**Abbreviations:** H\<E, hematoxylin and eosin; ICC, intrahepatic cholangiocarcinoma; UHRF2, ubiquitin-like with PHD and ring finger domains 2.](ott-10-5863Fig3){#f3-ott-10-5863}

![Prognostic significance was assessed by log-rank tests and Kaplan--Meier analysis.\
**Notes:** (**A**--**D**) Representative graphs of H\<E and immunohistochemical staining for UHRF2 in ICC samples: (**A**) absence; (**B**) low; (**C**) moderate; (**D**) strong. Scale bar: 100, 200 μm. (**E** and **F**). The effects of UHRF2 expression on prognosis in patients with ICC are illustrated.\
**Abbreviations:** H\<E, hematoxylin and eosin; ICC, intrahepatic cholangiocarcinoma; UHRF2, ubiquitin-like with PHD and ring finger domains 2.](ott-10-5863Fig4){#f4-ott-10-5863}

###### 

Correlations between UHRF2 with clinicopathologic features in 139 ICC patients

  Variable                        Number of patients   *P*-value   
  ------------------------------- -------------------- ----------- --------------------------------------------------
  **Age, years**                                                   0.865
  ≥53                             32                   38          
  \<;53                           30                   39          
  **Gender**                                                       1.000
  Men                             26                   32          
  Women                           36                   45          
  **HBsAg**                                                        0.726
  Positive                        37                   49          
  Negative                        25                   28          
  **Child--Pugh score**                                            0.089[a](#tfn1-ott-10-5863){ref-type="table-fn"}
  A                               5                    1           
  B                               57                   76          
  **Serum CA 19-9, ng/mL**                                         0.489
  ≥37                             40                   45          
  \<;37                           22                   32          
  **Serum ALT, U/L**                                               0.443
  ≥75                             10                   9           
  \<;75                           52                   68          
  **Serum AFP, ng/mL**                                             0.089
  ≥20                             12                   7           
  \<;20                           50                   70          
  **Cirrhosis**                                                    0.229
  Yes                             25                   33          
  No                              37                   44          
  **Microvascular invasion**                                       **0.028**
  Yes                             36                   30          
  No                              26                   47          
  **Tumor size (diameter, cm)**                                    0.838
  ≥5                              48                   61          
  \<;5                            14                   16          
  **Tumor number**                                                 0.218
  Multiple                        7                    4           
  Solitary                        55                   73          
  **Embolus**                                                      0.820
  Yes                             11                   12          
  No                              51                   65          
  **Lymphatic metastasis**                                         **0.009**
  Yes                             22                   12          
  No                              40                   65          
  **Tumor differentiation**                                        0.310
  III/IV                          33                   34          
  I/II                            29                   43          

**Notes:**

Fisher's exact test. UHRF2^high^ ≥50% staining; UHRF2^low^ \<;50% staining. Statistically significant values are shown in bold.

**Abbreviations:** AFP, α-fetoprotein; ALT, alanine aminotransferase; CA 19-9, carbohydrate antigen 19-9; HBsAg, hepatitis B surface antigen; ICC, intrahepatic cholangiocarcinoma; UHRF2, ubiquitin-like with PHD and ring finger domains 2.

###### 

Univariate and multivariate analyses of factors associated with recurrence and survival

  Variable                                         Overall survival   Cumulative recurrence                                          
  ------------------------------------------------ ------------------ ----------------------- ------- ------- ---------------------- -------
  Age, years (≥53 vs \<;53)                        0.529                                      NA      0.331                          NA
  Gender (men vs women)                            0.836                                      NA      0.697                          NA
  HBsAg (positive vs negative)                     0.659                                      NA      0.335                          NA
  Child--Pugh score (A vs B)                       0.132                                      NA      0.078                          NA
  Serum CA 19-9, ng/mL (≥37 vs \<;37)              0.483                                      NA      0.339                          NA
  Serum ALT, U/L (≥75 vs \<;75)                    0.585                                      NA      0.824                          NA
  Serum AFP, ng/mL (≥20 vs \<;20)                  0.259                                      NA      0.756                          NA
  Cirrhosis (yes vs no)                            0.382                                      NA      0.587                          NA
  Microvascular invasion (yes vs no)               0.243                                      NS      0.134                          NS
  Maximal tumor size (diameter, cm) (≥5 vs \<;5)   0.040                                      NS      0.007                          NS
  Tumor number (multiple vs solitary)              0.008                                      NS      0.002                          NS
  Embolus (yes vs no)                              0.036                                      NS      0.032                          NS
  Tumor differentiation (III/IV vs I/II)           0.028                                      NS      0.033                          NS
  Lymphatic metastasis (yes vs no)                 0.008              0.642 (0.418--0.986)    0.043   0.002   0.559 (0.336--0.853)   0.007
  UHRF2 density (\<;50% vs ≥50%)                   \<;0.001           0.004 (0.001--0.234)    0.008   0.042   0.013 (0.001--0.724)   0.034

**Abbreviations:** ALT, alanine aminotransferase; AFP, α-fetoprotein; CA 19-9, carbohydrate antigen 19-9; HBsAg, hepatitis B surface antigen; HR, hazard ratio; NA, not adopted; NS, not significant; UHRF2, ubiquitin-like with PHD and ring finger domains 2.
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